New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free

Tuesday, November 17, 2026

Back to the front page

From X

S&P Global

S&P Global’s valuation swung from 7x earnings in 2009 to 50x in 2024 as ratings, indices and proprietary data expanded through acquisitions…

Monte Investments Market Brief Vol. CXXXVI

Monte Investments rotated Nvidia into Alphabet before earnings and reviews Knife River’s margin squeeze, AMD’s World Labs acquisition, and…

Envisioning Entravision

Entravision’s AdTech revenue rose 133% and EBIT 261% in Q3 as management weighs TV-station sales before its TelevisaUnivision agreement…

SLS · short

Sellas Life Sciences Group I

SELLAS Life Sciences Group faces a short case arguing that even a strong clinical outcome does not support its current valuation.

Portfolio Updates

CYD was sold near $21 versus an $11 entry after exceeding a $19.50 target; proceeds moved to H22.SI, whose CYD stake implies $1.30 NAV and…

Fading a Myopic Sell-Off

Organigram’s shares fell 25% after Q1, despite Motif Labs making OGI Canada’s largest cannabis producer and a top-three player across major…

Key Takeaways from NVRs Deep Dive

NVR’s lot options and build-to-order homes limit land and inventory risk, driving capital efficiency, 20% to 40% ROE and resilience through…

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

383 firms

Sectors

Ordered by how often our editor reaches for them.